You might also like
Enovis Corporation (ENOV) is a global medical technology company dedicated to developing innovative solutions that enhance patient outcomes and streamline healthcare workflows. The company designs, manufactures, and distributes a wide range of medical devices, addressing the continuum of care from injury prevention to post-surgical rehabilitation. Its offerings include orthopedic solutions, reconstructive joint products, and surgical productivity tools, serving healthcare providers and patients worldwide.
- Prevention & Recovery (P&R) - Provides orthopedic solutions and recovery products, including rigid bracing, orthopedic soft goods, vascular systems, compression garments, hot and cold therapy devices, bone growth stimulators, and electrical stimulators for pain management.
- Reconstructive (Recon) - Offers surgical implants and reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, along with surgical productivity tools designed to improve surgical efficiency and outcomes.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Matthew L. Trerotola ExecutiveBoard | CEO and Chair of the Board | Director at AptarGroup, Inc. | Matthew L. Trerotola has been the CEO since July 2015 and Chair since 2023. He focuses on leveraging innovation to drive growth and margin improvements. | View Report → |
Brady R. Shirley Executive | Executive Advisor | None | Brady R. Shirley is an Executive Advisor focusing on integration and mentoring, having served as President and COO from 2022 to 2024. | |
Daniel A. Pryor Executive | Executive Vice President, Strategy and Business Development | None | Daniel A. Pryor has been with ENOV since 2011, focusing on strategy and business development. | |
Louis Vogt Executive | Group President, Reconstructive | None | Louis Vogt joined ENOV in 2017 and has driven growth in the U.S. surgical business. | |
Patricia Lang Executive | Senior Vice President and Chief Human Resources Officer | None | Patricia Lang has been leading HR and branding initiatives at ENOV since January 2019. [N/A] | |
Phillip B. Berry Executive | Senior Vice President and CFO | None | Phillip B. Berry joined ENOV in 2020 and became CFO on January 1, 2023. He has played a significant role in financial leadership and strategy. | |
Terry D. Ross Executive | Group President, Prevention & Recovery | None | Terry D. Ross joined ENOV in 2012 and has held various leadership roles, currently leading the Prevention & Recovery segment. | |
A. Clayton Perfall Board | Director | None | A. Clayton Perfall has been a director since 2010 and serves as Chair of the Audit Committee. | |
Angela S. Lalor Board | Director | None | Angela S. Lalor has been a director since 2022, with experience in leadership development and human capital management. | |
Barbara W. Bodem Board | Director | Director at BioMarin Pharmaceutical, Inc.; Director at Option Care Health, Inc.; Director at BiomEdit; Director at Northstar Medical Radioisotope | Barbara W. Bodem has been a director since 2022, with extensive finance and healthcare industry experience. | |
Dr. Christine Ortiz Board | Director | Professor at MIT; Director at Mueller Water Products, Inc. | Dr. Christine Ortiz has been a director since 2022, with expertise in biotechnology and advanced manufacturing. | |
Liam J. Kelly Board | Director | Chairman, President, and CEO of Teleflex Incorporated | Liam J. Kelly has been a director since 2020 and holds senior leadership roles at Teleflex. | |
Philip A. Okala Board | Director | COO at Tufts Medicine | Philip A. Okala has been a director since 2021, with significant healthcare industry experience. | |
Rajiv Vinnakota Board | Director | President of the Institute for Citizens & Scholars; Director at ESAB Corporation | Rajiv Vinnakota has been a director since 2008, with leadership roles in educational and civic organizations. | |
Sharon Wienbar Board | Lead Independent Director | Director at Resideo Technologies, Inc.; Director at Planned Parenthood Direct | Sharon Wienbar has been a director since 2016 and was appointed Lead Independent Director in 2023. |
- Given the ongoing dissynergies you've experienced, can you clarify the specific steps you're taking to mitigate these dissynergies and whether you expect any further impact in 2025?
- Despite your projections, free cash flow has been under pressure due to integration-related investments; can you provide more detail on your confidence in achieving positive free cash flow in fiscal '25 and the underlying factors driving this improvement?
- With the lowering of forward guidance for consecutive quarters and mention of slowness due to external factors like hurricanes and IV shortages, how are you adjusting your strategy to account for these challenges, and what measures are in place to prevent future guidance reductions?
- As competitors benefit from the cementless knee segment, what specific plans do you have to enhance your Knee portfolio to capture growth in this area, and how will you differentiate your offerings from the competition?
- Regarding your strategy to grow both by attracting new surgeons and expanding within your existing surgeon base, can you elaborate on the initiatives you are implementing to drive growth in each area in 2025, and how you expect these to impact your overall performance?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
LimaCorporate S.p.A. | 2024 | Enovis acquired LimaCorporate S.p.A. for an enterprise value of €800 million, with a structure combining approximately €700 million in cash (including debt repayment) and €100 million in contingent acquisition shares; the deal strengthens Enovis’s global orthopedic reconstruction market presence and adds advanced products like 3D printed Trabecular Titanium implants. |
Novastep | 2023 | Enovis completed the Novastep acquisition on June 28, 2023 for $96.9 million, enhancing its Foot & Ankle reconstructive segment with a best-in-class MIS bunion system and allocating $39.8 million to goodwill and $52 million to intangible assets to expand its global customer base, especially in Europe. |
SEAL External Fixation Product Line | 2023 | Acquired on July 20, 2023 for $28.2 million, the SEAL product line deal added key external fixation products—allocated as $25.8 million to intangible assets, $1.9 million to inventory, and $0.5 million to PP&E—to enhance Enovis's offerings in the foot and ankle market. |
360 Med Care Pty Ltd | 2022 | Enovis acquired 360 Med Care Pty Ltd on May 6, 2022 for $14.3 million (plus $12.8 million contingent consideration), broadening its customer base in Australia while enhancing its portfolio with digital technologies and computer-assisted surgery capabilities. |
Insight Medical Systems | 2022 | The step-acquisition of Insight Medical Systems on July 5, 2022, involved an additional 53.7% interest for $34.2 million plus up to $5.0 million in contingent consideration, securing a 99.5% ownership in a company with the ARVIS augmented reality system for hip and knee replacements, with the acquisition yielding $36.3 million in goodwill and $38.4 million in intangible assets. |
Recent press releases and 8-K filings for ENOV.
- Sales & Growth: Q1 2025 sales reached $559 million with +8% reported and +10% comparable growth, driven by strong overall performance .
- Margin & Operational Highlights: Expanded adjusted EBITDA margin by 160bps to 17.7%, with adjusted EBITDA of $99M and a 350bps tailwind from additional selling days .
- Segment Performance: The Recon segment grew 13% and the Prevention & Recovery segment saw 8% growth, evidencing robust market traction .
- Guidance Update: 2025 outlook now projects revenue between $2.22-2.25B with revised adjusted EBITDA expectations—target lowered by $20M due to anticipated tariff headwinds .
- Strategic Initiatives: New product launches, including the augmented reverse glenoid system and the Manafuse LIPUS device, are underway alongside efforts to shift sourcing out of China to mitigate tariff impact .
- CEO Appointment: Damien McDonald appointed CEO, effective May 12, 2025, marking a new leadership phase .
- CEO Transition: CEO Matt Trerotola is retiring and will be succeeded by Damien McDonald, effective mid-May 2025, following a planned succession process.
- Product Innovation: Enovis continues to gain market share in its reconstructive business with standout products like the AltiVate shoulder system and EMPOWR 3D knee, delivering improved patient satisfaction and competitive outcomes.
- Lima Acquisition Synergies: The Lima acquisition is performing ahead of expectations, with cost synergies in Year 1 approaching $20 million and a target of over $40 million by Year 3.
- Ambulatory Expansion: The company is also expanding its presence in ambulatory surgical centers, enhancing its product offerings with enabling technologies like Arvis to support navigation, guidance, and potential future robotic applications.
- Damien McDonald, a veteran with over 35 years in the medical device industry, has been appointed as CEO, effective May 12, 2025 ( ).
- The leadership transition includes board changes, with McDonald joining the board after the annual meeting on May 21, 2025, and the current CEO, Matt Trerotola, retiring ( ).
- The company also reaffirmed its Q1 2025 guidance, expecting revenues of $555–$563 million and adjusted EBITDA between $97–$100 million ( ).
- Enovis is leveraging its clinical differentiation in shoulder and knee implant technologies, achieving significant market share—17% in the U.S. and 28% internationally in the reverse shoulder segment.
- The recent Lima acquisition added nearly $350 million in revenue and advanced additive manufacturing capabilities, expanding the company’s global footprint.
- The company is investing in robotics and augmented reality innovations, with new navigation solutions poised to enhance surgical precision across shoulder, knee, and hip procedures.
- Discussion also highlighted strong volume trends and disciplined pricing performance, consistently exceeding market pricing by about 50 basis points.
- CEO Retirement Announcement: Enovis Corporation announced that CEO Matthew L. Trerotola will retire upon the appointment of his successor, and he will continue serving as a Special Advisor during the transition period, which lasts one year after the successor’s appointment.
- Compensation Details: During the transition, Mr. Trerotola will receive his current base salary through the second full calendar month post-appointment, followed by a reduced salary (not less than 50% of his current base), along with eligibility for a 2025 annual bonus and a pro-rated bonus for 2026.
- Ongoing Obligations: The agreement imposes restrictive covenants, including non-compete, non-solicitation, confidentiality, and non-disparagement obligations that extend for a specified period following the transition.
- Enovis detailed its ongoing transformation by growing from a $1.2 billion to over $2 billion company through both organic initiatives and strategic acquisitions, including the recent integration of Lima to enhance its global reach.
- The company reported robust Q4 momentum with double-digit growth in its Recon business, 3% growth in its Prevention & Recovery segment, and a 210 basis point improvement in profit margins, setting a positive tone for 2025 guidance.
- Executives addressed potential impacts from Mexican tariffs on its Prevention & Recovery operations and emphasized proactive mitigation measures, including diversifying manufacturing locations.
- The call also noted the upcoming retirement of CEO Matt Trerotola after more than 10 years at the helm, signaling a leadership transition while the search for a new CEO remains ongoing.